Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group

Presse Medicale

Volumn 43, Issue 10, 2014, Pages e345-e363

  Launay, David ^a,b,c   Savale, Laurent ^d,e,f   Berezne, Alice ^g   Le Pavec, JérÔme ^d,f   Hachulla, Eric ^a,b,c   Mouthon, Luc ^g   Sitbon, Olivier ^d,e,f   Lambert, Benoit ^e   Gaudric, Marianne ^f   Jais, Xavier ^d,e,f   Stephan, Francois ^g   Hatron, Pierre Yves ^a,b   Lamblin, Nicolas ^a,b   Vignaux, Olivier ^g   Cottin, Vincent ^h   Farge, Dominique ⁱ   Wallaert, Benoît ^a,b   Guillevin, Loic ^g   Simonneau, Gerald ^d,e,f   Mercier, Olaf ^d,f   Fadel, Elie ^d,f   Dartevelle, Philippe ^d,f   Humbert, Marc ^d,e,f   Mussot, Sacha ^d,f   more..

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c EA2686   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e BICÊTRE HOSPITAL   (France)

^f CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^g Vasculaire et de transplantation cardiopulmonaire ^*  (France)

^h UNIVERSITÉ LYON 1   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

BACTERIAL PNEUMONIA; BRONCHIOLITIS OBLITERANS; CARDIAC GRAFT REJECTION; CHRONIC KIDNEY FAILURE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; FINGER AMPUTATION; FINGER ULCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GRAFT FAILURE; HEART DISEASE; HEART LUNG TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; INTESTINE PSEUDOOBSTRUCTION; KAPOSI SARCOMA; KIDNEY DISEASE; LUNG ASPERGILLOSIS; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALABSORPTION; MEDICAL RECORD REVIEW; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREOPERATIVE TREATMENT; PULMONARY HYPERTENSION; QUALITY OF LIFE; SCLERODERMA RENAL CRISIS; SHORT SURVEY; SKIN DISEASE; STOMACH PARESIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC SCLEROSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUBERCULOUS PLEURISY; COMPLICATION; HEART DISEASES; LUNG DISEASES; MIDDLE AGED; RETROSPECTIVE STUDY; SCLERODERMA, SYSTEMIC;

HEART DISEASES; HEART-LUNG TRANSPLANTATION; HUMANS; LUNG DISEASES; MIDDLE AGED; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 84908548314     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.01.020     Document Type: Short Survey

References (135)

1. Le Pavec J., Launay D., Mathai S.C., Hassoun P.M., Humbert M. Scleroderma lung disease. Clin Rev Allergy Immunol 2011, 40:104-116.
2. Hassoun P.M. Lung involvement in systemic sclerosis. Presse Med 2011, 40:e3-e17.
3. Le Pavec J., Humbert M., Mouthon L., Hassoun P.M. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2010, 181:1285-1293.
4. Hachulla E., Launay D., Yaici A., Berezne A., de Groote P., Sitbon O., et al. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology 2010, 49:940-944.
5. Launay D., Remy-Jardin M., Michon-Pasturel U., Mastora I., Hachulla E., Lambert M., et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006, 33:1789-1801.
6. Launay D., Mouthon L., Hachulla E., Pagnoux C., de Groote P., Remy-Jardin M., et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 2007, 34:1005-1011.
7. Berezne A., Valeyre D., Ranque B., Guillevin L., Mouthon L. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?. Ann N Y Acad Sci 2007, 1110:271-284.
8. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
9. Hachulla E., Carpentier P., Gressin V., Diot E., Allanore Y., Sibilia J., et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology 2009, 48:304-308.
10. Mathai S.C., Hummers L.K., Champion H.C., Wigley F.M., Zaiman A., Hassoun P.M., et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009, 60:569-577.
11. Lefèvre G., Dauchet L., Hachulla E., Montani D., Sobanski V., Lambert M., et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 2013, 65:2412-2423.
12. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34:1219-1263.
13. Condliffe R., Kiely D.G., Peacock A.J., Corris P.A., Gibbs J.S., Vrapi F., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009, 179:151-157.
14. Günther S., Jais X., Maitre S., Berezne A., Dorfmuller P., Seferian A., et al. Computed tomography findings of pulmonary veno-occlusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum 2012, 64:2995-3005.
15. Dorfmuller P., Humbert M., Perros F., Sanchez O., Simonneau G., Muller K.M., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007, 38:893-902.
16. Montani D., Achouh L., Dorfmuller P., Le Pavec J., Sztrymf B., Tcherakian C., et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine 2008, 87:220-233.
17. Montani D., Kemp K., Dorfmuller P., Sitbon O., Simonneau G., Humbert M. Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. Semin Respir Crit Care Med 2009, 30:411-420.
18. Montani D., Jais X., Dorfmuller P., Simonneau G., Sitbon O., Humbert M. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. Eur Respir J 2009, 34:1204-1206.
19. Montani D., Achouh L., Sitbon O., Simonneau G., Humbert M. Pulmonary venoocclusive disease and failure of specific therapy. Chest 2009, 136:1181. [author reply 1181-2].
20. Dorfmuller P., Montani D., Humbert M. Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension. Eur Respir J 2010, 35:6-8.
21. Tashkin D.P., Elashoff R., Clements P.J., Roth M.D., Furst D.E., Silver R.M., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007, 176:1026-1034.
22. Trulock E.P., Edwards L.B., Taylor D.O., Boucek M.M., Mohacsi P.J., Keck B.M., et al. The Registry of the International Society for Heart and Lung Transplantation: twentieth Official adult lung and heart-lung transplant report-2003. J Heart Lung Transplant 2003, 22:625-635.
23. Schachna L., Medsger T.A., Dauber J.H., Wigley F.M., Braunstein N.A., White B., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006, 54:3954-3961.
24. Saggar R., Khanna D., Furst D.E., Belperio J.A., Park G.S., Weigt S.S., et al. Systemic sclerosis and bilateral lung transplantation: a single center experience. Eur Respir J 2010, 36:893-900.
25. de Perrot M., Granton J.T., McRae K., Pierre A.F., Singer L.G., Waddell T.K., et al. Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience. J Thorac Cardiovasc Surg 2012, 143:910-918.
26. Massad M.G., Powell C.R., Kpodonu J., Tshibaka C., Hanhan Z., Snow N.J., et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg 2005, 29:1510-1515.
27. Shitrit D., Amital A., Peled N., Raviv Y., Medalion B., Saute M., et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant 2009, 23:178-183.
28. Sottile P.D., Iturbe D., Katsumoto T.R., Connolly M.K., Collard H.R., Leard L.A., et al. Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transplanation 2013, 95:975-980.
29. Masi A.T. Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol 1988, 15:894-898.
30. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
31. Orens J.B., Estenne M., Arcasoy S., Conte J.V., Corris P., Egan J.J., et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006, 25:745-755.
32. Wells A.U. High-resolution computed tomography and scleroderma lung disease. Rheumatology 2008, 47(Suppl 5):v59-v61.
33. Trulock E.P., Edwards L.B., Taylor D.O., Boucek M.M., Keck B.M., Hertz M.I. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report-2005. J Heart Lung Transplant 2005, 24:956-967.
34. Estenne M., Maurer J.R., Boehler A., Egan J.J., Frost A., Hertz M., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002, 21:297-310.
35. Montani D., Price L.C., Dorfmuller P., Achouh L., Jais X., Yaici A., et al. Pulmonary veno-occlusive disease. Eur Respir J 2009, 33:189-200.
36. Levine R.J., Boshell B.R. Renal involvement in progressive systemic sclerosis (scleroderma). Ann Intern Med 1960, 52:517-529.
37. Levine S.M., Anzueto A., Peters J.I., Calhoon J.H., Jenkinson S.G., Bryan C.L. Single lung transplantation in patients with systemic disease. Chest 1994, 105:837-841.
38. Khan I.Y., Singer L.G., de Perrot M., Granton J.T., Keshavjee S., Chau C., et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med 2013, 107:2081-2087.
39. Maurer J.R., Frost A.E., Estenne M., Higenbottam T., Glanville A.R. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 1998, 66:951-956.
40. Mouthon L., Berezne A., Brauner M., Kambouchner M., Guillevin L., Valeyre D. [Interstitial lung disease in systemic sclerosis]. Presse Med 2006, 35:1943-1951.
41. Bouros D., Wells A.U., Nicholson A.G., Colby T.V., Polychronopoulos V., Pantelidis P., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165:1581-1586.
42. Goh N.S., Desai S.R., Veeraraghavan S., Hansell D.M., Copley S.J., Maher T.M., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248-1254.
43. Trad S., Amoura Z., Beigelman C., Haroche J., Costedoat N., Boutin le T.H., et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006, 54:184-191.
44. Launay D., Humbert M., Berezne A., Cottin V., Allanore Y., Couderc L.J., et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011, 140:1016-1024.
45. Le Pavec J., Girgis R.E., Lechtzin N., Mathai S.C., Launay D., Hummers L.K., et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011, 63:2456-2464.
46. Desai S.R., Veeraraghavan S., Hansell D.M., Nikolakopolou A., Goh N.S., Nicholson A.G., et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004, 232:560-567.
47. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2656.
48. Hoyles R.K., Ellis R.W., Wellsbury J., Lees B., Newlands P., Goh N.S., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54:3962-3970.
49. Burt R.K., Shah S.J., Dill K., Grant T., Gheorghiade M., Schroeder J., et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011, 378:498-506.
50. Berezne A., Ranque B., Valeyre D., Brauner M., Allanore Y., Launay D., et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 2008, 35:1064-1072.
51. Manes A., Marinelli A., Palazzini M., Negro L., Leci E., Gambetti S., et al. [Pulmonary arterial hypertension. Part II: Medical and surgical treatment]. G Ital Cardiol 2009, 10:366-381.
52. Hachulla E., Launay D., Le Pavec J., Mouthon L., Guillevin L., de Groote P. [Systemic sclerosis associated pulmonary arterial hypertension: the pitfalls]. Presse Med 2011, 40:1S46-53S.
53. Launay D., Humbert M., Hachulla E. [Pulmonary arterial hypertension and systemic sclerosis]. Presse Med 2006, 35:1929-1937.
54. Launay D., Sitbon O., Le Pavec J., Savale L., Tcherakian C., Yaici A., et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology 2010, 49:490-500.
55. Campo A., Mathai S.C., Le Pavec J., Zaiman A.L., Hummers L.K., Boyce D., et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010, 182:252-260.
56. Johnson S.R., Swiston J.R., Granton J.T. Prognostic factors for survival in scleroderma associated pulmonary arterial hypertension. J Rheumatol 2008, 35:1584-1590.
57. Johnson S.R., Granton J.T. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev 2011, 20:277-286.
58. Avouac J., Kowal-Bielecka O., Pittrow D., Huscher D., Behrens F., Denton C.P., et al. Validation of the 6min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis 2010, 69:1360-1363.
59. Montani D., Jais X., Price L.C., Achouh L., Degano B., Mercier O., et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009, 34:1348-1356.
60. Montani D., O'Callaghan D.S., Savale L., Jais X., Yaici A., Maitre S., et al. Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 2010, 104:S23-S32.
61. Kawaguchi Y., Hara M., Harigai M., Sakurada M., Nakamura H., Kashiwazaki S. Corticosteroid pulse therapy in a patient with SLE and pulmonary hypertension. Clin Exp Rheumatol 1998, 16:510.
62. Guillevin L. [Digital ulcers in systemic sclerosis]. Presse Med 2008, 37:735-736.
63. Hachulla E., Clerson P., Launay D., Lambert M., Morell-Dubois S., Queyrel V., et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007, 34:2423-2430.
64. Denton C.P., Krieg T., Guillevin L., Schwierin B., Rosenberg D., Silkey M., et al. Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis 2012, 71:718-721.
65. Teixeira L., Mouthon L., Mahr A., Berezne A., Agard C., Mehrenberger M., et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008, 67:110-116.
66. Guillevin L., Berezne A., Seror R., Teixeira L., Pourrat J., Mahr A., et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology 2012, 51:460-467.
67. Penn H., Howie A.J., Kingdon E.J., Bunn C.C., Stratton R.J., Black C.M., et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007, 100:485-494.
68. Penn H., Denton C.P. Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol 2008, 20:692-696.
69. Teixeira L., Mahr A., Berezne A., Noel L.H., Guillevin L., Mouthon L. Scleroderma renal crisis, still a life-threatening complication. Ann N Y Acad Sci 2007, 1108:249-258.
70. Zachariae H., Hansen H.E., Olsen T.S. Hemolytic uremic syndrome in a patient with systemic sclerosis treated with cyclosporin A. Acta Derm Venereol 1992, 72:307-309.
71. Marie I., Dominique S., Levesque H., Ducrotte P., Denis P., Hellot M.F., et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001, 45:346-354.
72. Savarino E., Bazzica M., Zentilin P., Pohl D., Parodi A., Cittadini G., et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009, 179:408-413.
73. Hadjiliadis D., Duane Davis R., Steele M.P., Messier R.H., Lau C.L., Eubanks S.S., et al. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant 2003, 17:363-368.
74. D'Ovidio F., Mura M., Tsang M., Waddell T.K., Hutcheon M.A., Singer L.G., et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005, 129:1144-1152.
75. D'Ovidio F., Keshavjee S. Gastroesophageal reflux and lung transplantation. Dis Esophagus 2006, 19:315-320.
76. D'Ovidio F., Mura M., Ridsdale R., Takahashi H., Waddell T.K., Hutcheon M., et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am J Transplant 2006, 6:1930-1938.
77. Hoppo T., Jobe B.A. Diagnosis and management of GERD before and after lung transplantation. Thorac Surg Clin 2011, 21:499-510.
78. Gasper W.J., Sweet M.P., Golden J.A., Hoopes C., Leard L.E., Kleinhenz M.E., et al. Lung transplantation in patients with connective tissue disorders and esophageal dysmotility. Dis Esophagus 2008, 21:650-655.
79. Gasper W.J., Sweet M.P., Hoopes C., Leard L.E., Kleinhenz M.E., Hays S.R., et al. Antireflux surgery for patients with end-stage lung disease before and after lung transplantation. Surg Endosc 2008, 22:495-500.
80. Sweet M.P., Patti M.G., Hoopes C., Hays S.R., Golden J.A. Gastro-oesophageal reflux and aspiration in patients with advanced lung disease. Thorax 2009, 64:167-173.
81. Wipff J., Giraud M., Sibilia J., Mouthon L., Meyer O., Tiev K., et al. Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. J Rheumatol 2008, 35:643-649.
82. Blondeau K., Dupont L.J., Mertens V., Verleden G., Malfroot A., Vandenplas Y., et al. Gastro-oesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis. Gut 2008, 57:1049-1055.
83. Robertson A.G., Shenfine J., Ward C., Pearson J.P., Dark J.H., Corris P.A., et al. A call for standardization of antireflux surgery in the lung transplantation population. Transplantation 2009, 87:1112-1114.
84. Domsic R., Fasanella K., Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci 2008, 53:1163-1174.
85. Ranque B., Authier F.J., Berezne A., Guillevin L., Mouthon L., et al. Systemic sclerosis-associated myopathy. Y Acad Sci 2007, 1108:268-282.
86. Ranque B., Authier F.J., Le-Guern V., Pagnoux C., Berezne A., Allanore Y., et al. A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 2009, 68:1474-1477.
87. Kahan A., Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology 2006, 45(Suppl.4):iv14-iv17.
88. Allanore Y., Meune C., Kahan A. Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol 2008, 20:697-702.
89. Allanore Y., Meune C., Kahan A. Outcome measures for heart involvement in systemic sclerosis. Rheumatology 2008, 47(Suppl 5):v51-v53.
90. Allanore Y., Kahan A. [Heart involvement in systemic sclerosis]. Presse Med 2006, 35:1938-1942.
91. Allanore Y., Meune C., Vonk M.C., Airo P., Hachulla E., Caramaschi P., et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010, 69:218-221.
92. Meune C., Allanore Y., Devaux J.Y., Dessault O., Duboc D., Weber S., et al. High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. J Rheumatol 2004, 31:1941-1945.
93. Meune C., Allanore Y. Abnormal right ventricular diastolic function may not be the only early marker of myocardial involvement in systemic sclerosis. Chest 2006, 130:302.
94. Meune C., Avouac J., Wahbi K., Cabanes L., Wipff J., Mouthon L., et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008, 58:1803-1809.
95. Meune C., Vignaux O., Kahan A., Allanore Y. Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 2010, 103:46-52.
96. de Groote P., Gressin V., Hachulla E., Carpentier P., Guillevin L., Kahan A., et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008, 67:31-36.
97. Kostis J.B., Seibold J.R., Turkevich D., Masi A.T., Grau R.G., Medsger T.A., et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med 1988, 84:1007-1015.
98. Paradiso M., Gabrielli F., Coppotelli L., Aguglia G., Pergolini M., Leonardo M., et al. Signal-averaged electrocardiography and echocardiography in the evaluation of myocardial involvement in progressive systemic sclerosis. Int J Cardiol 1996, 53:171-177.
99. Paradiso M., Di Franco M., Musca A., Basili S., Riccieri V., Paoletti V., et al. Ventricular late potentials in systemic sclerosis: relationship with skin involvement. J Rheumatol 2002, 29:1388-1392.
100. Fox B.D., Shimony A., Langleben D., Hirsch A., Rudski L., Schlesinger R., et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J 2013, 42:1083-1091.
101. Hachulla A.L., Launay D., Gaxotte V., de Groote P., Lamblin N., Devos P., et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009, 68:1878-1884.
102. Bezante G.P., Rollando D., Sessarego M., Panico N., Setti M., Filaci G., et al. Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol 2007, 34:2431-2437.
103. Kowal-Bielecka O., Landewe R., Avouac J., Chwiesko S., Miniati I., Czirjak L., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009, 68:620-628.
104. Korn J.H., Mayes M., Matucci Cerinic M., Rainisio M., Pope J., Hachulla E., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985-3993.
105. Venitz J., Zack J., Gillies H., Allard M., Regnault J., Dufton C. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol 2012, 52:1784-1805.
106. Hudson M., Baron M., Lo E., Weinfeld J., Furst D.E., Khanna D. An international, web-based prospective cohort study to determine whether the use of ACE inhibitors prior to the onset of scleroderma renal crisis is associated with worse outcomes-methodology and preliminary results. Int J Rheumatol 2010, 2010. [pii 347402].
107. Neurohr C., Huppmann P., Thum D., Leuschner W., von Wulffen W., Meis T., et al. Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis. Transplant Int 2010, 23:887-896.
108. Meune C., Allanore Y., Pascal O., Devaux J.Y., Dessault O., Duboc D., et al. Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. Eur J Echocardiogr 2005, 6:351-357.
109. Meune C., Allanore Y., Vignaux O., Merceron O., Assous N., Legmann P., et al. Predominant primitive right ventricular involvement in systemic sclerosis. Clin Exp Rheumatol 2007, 25:658.
110. Fadel E., Mercier O., Mussot S., Leroy-Ladurie F., Cerrina J., Chapelier A., et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardiothorac Surg 2010, 38:277-284.
111. Forfia P.R., Fisher M.R., Mathai S.C., Housten-Harris T., Hemnes A.R., Borlaug B.A., et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006, 174:1034-1041.
112. Ghio S., Klersy C., Magrini G., D'Armini A.M., Scelsi L., Raineri C., et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2010, 140:272-278.
113. van de Veerdonk M.C., Kind T., Marcus J.T., Mauritz G.J., Heymans M.W., Bogaard H.J., et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011, 58:2511-2519.
114. Hachulla E., Launay D., Hatron P.Y. [Iloprost for the treatment of systemic sclerosis]. Presse Med 2008, 37:831-839.
115. Wigley F.M., Seibold J.R., Wise R.A., McCloskey D.A., Dole W.P. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992, 19:1407-1414.
116. Linden P.A., Gilbert R.J., Yeap B.Y., Boyle K., Deykin A., Jaklitsch M.T., et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006, 131:438-446.
117. Fiorucci S., Distrutti E., Bassotti G., Gerli R., Chiucchiu S., Betti C., et al. Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scand J Gastroenterol 1994, 29:807-813.
118. Witt C.A., Hachem R.R. Immunosuppression: what's standard and what's new?. Semin Respir Crit Care Med 2013, 34:405-413.
119. Young B.A., Marsh C.L., Alpers C.E., Davis C.L. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis 1996, 28:561-571.
120. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 2005, 24:119-130.
121. Keenan R.J., Konishi H., Kawai A., Paradis I.L., Nunley D.R., Iacono A.T., et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995, 60:580-584. [discussion 584-5].
122. Zuckermann A., Reichenspurner H., Birsan T., Treede H., Deviatko E., Reichart B., et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg 2003, 125:891-900.
123. Treede H., Klepetko W., Reichenspurner H., Zuckermann A., Meiser B., Birsan T., et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001, 20:511-517.
124. Hachem R.R., Yusen R.D., Chakinala M.M., Meyers B.F., Lynch J.P., Aloush A.A., et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 2007, 26:1012-1018.
125. Briffa N., Morris R.E. New immunosuppressive regimens in lung transplantation. Eur Respir J 1997, 10:2630-2637.
126. Israni A., Brozena S., Pankewycz O., Grossman R., Bloom R. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. Am J Kidney Dis 2002, 39:E16.
127. Christie J.D., Edwards L.B., Kucheryavaya A.Y., Aurora P., Dobbels F., Kirk R., et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010, 29:1104-1118.
128. McNeil K., Glanville A.R., Wahlers T., Knoop C., Speich R., Mamelok R.D., et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 2006, 81:998-1003.
129. Palmer S.M., Baz M.A., Sanders L., Miralles A.P., Lawrence C.M., Rea J.B., et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001, 71:1772-1776.
130. Nihtyanova S.I., Denton C.P. Current approaches to the management of early active diffuse scleroderma skin disease. Rheum Dis Clin North Am 2008, 34:161viii-179viii.
131. Verrecchia F., Michel L., Keshtmand H., Wang Y., Launay D., Farge D. [Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?]. Rev Med Int 2009, 30:955-962.
132. Guilpain P., Servettaz A., Goulvestre C., Barrieu S., Borderie D., Chereau C., et al. Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. Arthritis Rheum 2007, 56:2455-2463.
133. Verrecchia F., Wang Y., Vija L., Farge D. Evidence of an antifibrotic effect of immunosuppressive drugs: applications in the treatment of systemic sclerosis. Expert Rev Clin Immunol 2009, 5:35-43.
134. Roos N., Poulalhon N., Farge D., Madelaine I., Mauviel A., Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007, 321:583-589.
135. Becker M.O., Bruckner C., Scherer H., Wasserman N., Humrich J.Y., Hanitsch L.G., et al. The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study. Ann Rheum Dis 2011, 70:1340-1341.